vimarsana.com
Home
Live Updates
Progress for Johnson & Johnsons lung cancer drug : vimarsana.com
Progress for Johnson & Johnson's lung cancer drug
The Janssen Pharmaceutical Companies of Johnson & Johnson announced last week (November 23) the submission of a type 2 extension of indication application to the European Medicines Agency (EMA).
Related Keywords
Catherine Taylor ,
European Medicines Agency ,
Janssen Research Development ,
European Commission ,
Kiran Patel ,
Janssen Research ,
Clinical Development ,
Preclinical Research ,
Drug Delivery ,
Ingredients ,
Markets Amp Regulations ,
Atient Centricity ,
Pis Active Pharmaceutical Ingredients ,
Young ,
Lung Cancer ,
Non Small Cell Lung Cancer ,
Ohnson Amp Johnson ,
Janssen ,
vimarsana.com © 2020. All Rights Reserved.